

PFIZER INC.

This document is provided pursuant to Regulation (EC) No 1901/2006 and Communication (2009/C 28/01)

PROPRIETARY DRUG NAME®/GENERIC DRUG NAME:

Braftovi/encorafenib

PROTOCOL NO.:

ARRAY-162-115 (C4221011)

EudraCT NUMBER:

2008-001946-32

PROTOCOL TITLE:

A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma

STUDY INITIATION DATE: August 3, 2020

STUDY COMPLETION DATE: August 19, 2022

PHASE OF DEVELOPMENT:

Phase 1

PROTOCOL STATUS: Terminated

The trial was terminated early on 05 October 2022 due to non-feasibility and poor recruitment and not based on safety concerns.

RESULTS:

The study did not recruit the desired number of subjects and as a result does not have sufficient data for quantitative statistical analyses. Additionally, results data cannot be reported because doing so would risk re-identification of the participant.